IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
-0.49%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$312M
AUM Growth
+$312M
(+3,153%)
Cap. Flow
+$279M
Cap. Flow
% of AUM
89.54%
Top 10 Holdings %
Top 10 Hldgs %
48.33%
Holding
84
New
6
Increased
59
Reduced
1
Closed
18
Top Buys
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$26.7M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$21.2M |
| 3 |
Incyte
INCY
|
$18M |
| 4 |
Alkermes
ALKS
|
$13.2M |
| 5 |
Gilead Sciences
GILD
|
$12.3M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$1.94M |
| 2 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$121K |
| 3 |
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
|
$107K |
| 4 |
Amicus Therapeutics
FOLD
|
$94.6K |
| 5 |
Immunovant
IMVT
|
$60K |
Sector Composition
| 1 | Healthcare | 99.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $28.2M | 9.03% | 454,973 +432,058 | +1,885% | +$26.7M |
|
|
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
| $22.7M | 7.29% | 166,200 +154,593 | +1,332% | +$21.2M |
|
|
3
Incyte
INCY
$16.5B
| $19.3M | 6.17% | 289,000 +270,919 | +1,498% | +$18M |
|
|
4
Alkermes
ALKS
$4.78B
| $13.2M | 4.25% | 593,000 +591,481 | +38,939% | +$13.2M |
|
|
5
Gilead Sciences
GILD
$140B
| $12.9M | 4.13% | 208,784 +199,772 | +2,217% | +$12.3M |
|
6
Biogen
BIIB
$19.4B
| $12.1M | 3.9% | 45,500 +34,894 | +329% | +$9.32M |
|
7
Harmony Biosciences
HRMY
$2.12B
| $11.7M | 3.76% | 264,500 +253,706 | +2,350% | +$11.2M |
|
|
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $10.3M | 3.3% | 221,856 +218,253 | +6,058% | +$10.1M |
|
9
uniQure
QURE
$896M
| $10.2M | 3.27% | 544,500 +536,182 | +6,446% | +$10.1M |
|
10
Supernus Pharmaceuticals
SUPN
$2.53B
| $10.1M | 3.23% | 297,500 +288,896 | +3,358% | +$9.78M |
|
|
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $9.5M | 3.05% | 136,000 +126,869 | +1,389% | +$8.86M |
|
12
Exelixis
EXEL
$10.1B
| $8.51M | 2.73% | 543,000 +535,710 | +7,349% | +$8.39M |
|
|
13
Regeneron Pharmaceuticals
REGN
$61.5B
| $7.72M | 2.47% | 11,200 -2,810 | -20% | -$1.94M |
|
14
Alnylam Pharmaceuticals
ALNY
$58.5B
| $7.6M | 2.44% | 38,000 +32,458 | +586% | +$6.49M |
|
15
Ultragenyx Pharmaceutical
RARE
$2.89B
| $7.2M | 2.31% | 174,052 +164,442 | +1,711% | +$6.8M |
|
|
KDNY
16
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $6.69M | 2.14% | 340,389 +334,442 | +5,624% | +$6.57M |
|
17
Vera Therapeutics
VERA
$1.38B
| $5.99M | 1.92% | 281,257 +277,432 | +7,253% | +$5.91M |
|
18
Sanofi
SNY
$121B
| $5.46M | 1.75% | 143,500 +141,924 | +9,005% | +$5.4M |
|
19
Galapagos
GLPG
$2.07B
| $5.25M | 1.68% | 123,300 +116,424 | +1,693% | +$4.96M |
|
20
BioMarin Pharmaceuticals
BMRN
$11.2B
| $4.97M | 1.59% | 58,656 +52,055 | +789% | +$4.41M |
|
21
Illumina
ILMN
$15.8B
| $4.77M | 1.53% | 25,000 +16,150 | +182% | +$3.08M |
|
22
KalVista Pharmaceuticals
KALV
$678M
| $4.59M | 1.47% | 316,133 +312,373 | +8,308% | +$4.53M |
|
23
Travere Therapeutics
TVTX
$1.56B
| $4.58M | 1.47% | 186,019 +176,804 | +1,919% | +$4.36M |
|
24
Dyne Therapeutics
DYN
$1.92B
| $4.44M | 1.42% | 350,068 +346,203 | +8,957% | +$4.39M |
|
25
Aurinia Pharmaceuticals
AUPH
$1.58B
| $4.31M | 1.38% | 573,530 +567,772 | +9,861% | +$4.27M |
|